Revenue segments as reported by the company.

Product revenues, net

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development expenses

Acquired in-process research and development expenses

Selling, general and administrative expenses

Change in fair value of contingent consideration

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Vertex Pharmaceuticals

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vertex Pharmaceuticals reports robust earnings, eyes growth in diverse therapies

Vertex Pharmaceuticals delivered strong financial results, provided optimistic revenue guidance for 2023, and emphasized investments in R&D and commercial capabilities. The company faces challenges with escalating costs and the need for clearer long-term financial goals. However, Vertex remains well-positioned to capitalize on growth opportunities in the healthcare market.

Vertex Pharmaceuticals reports robust Q1 growth and innovative pipeline

Vertex Pharmaceuticals had a strong Q1 2023 performance with revenue growth and ongoing investments in innovative therapies.
The company faces challenges in managing operating expenses and ensuring successful launches amidst competitive pressures.
However, Vertex's strengths lie in its diverse pipeline, regulatory approvals, and focus on transformative therapies.
Opportunities exist in addressing unmet medical needs, pursuing revenue growth in pain relief markets, and advancing non-opioid treatments.

Vertex Pharmaceuticals reports robust Q2 growth and pipeline advancements

Vertex Pharmaceuticals showed strong revenue growth and pipeline progress.
Challenges include slower uptake for gene therapies and market access.
Opportunities lie in reimbursement models, new therapy launches, and program advancements.
Overall, Vertex is strategically positioned for growth and innovation.

Vertex Pharmaceuticals reports strong Q3 growth and pipeline optimism

Vertex Pharmaceuticals shows solid financial performance and a robust pipeline of innovative therapies.
Challenges include navigating patient complexities, regulatory reviews, and market differentiation.
Opportunities lie in market expansion, therapeutic advancements, and strategic growth initiatives.
Overall, Vertex's focus on autonomy, innovation, and financial strength positions it for future success.

Vertex Pharmaceuticals reports robust Q4 earnings and strategic advancements

Vertex Pharmaceuticals delivered a strong performance in Q4 2023, driven by revenue growth, positive trial outcomes, and strategic advancements in its pipeline.
The company's focus on commercial diversification, regulatory approvals, and upcoming milestones in 2024 position Vertex well for continued success and growth.
While facing challenges related to patient targeting, physician capacity, and market differentiation, Vertex has opportunities to innovate, expand its reach, and enhance market positioning.
Overall, Vertex Pharmaceuticals' 2023 achievements, financial strength, and strategic initiatives underscore a promising outlook for the company's future growth and success.

Vertex Pharmaceuticals reports strong Q1 earnings and pipeline advancements

Vertex Pharmaceuticals demonstrated robust financial performance and strategic advancements in its pipeline and acquisitions, positioning itself for continued growth.
While facing challenges in commercialization and policy landscape, Vertex's strong financial position and innovative capabilities provide a solid foundation for future success.
With a focus on rare diseases, pain management, and revenue diversification, Vertex is poised to capitalize on market opportunities and drive innovation in healthcare.

Vertex Pharmaceuticals delivered strong revenue growth driven by key product demand, while facing increased operating expenses.
The company is focused on expanding its pipeline and accelerating new therapy launches amidst regulatory and commercial challenges.
Anticipation is high for upcoming launches like vanzacaftor and suzetrigine, signaling potential growth opportunities for Vertex.

Vertex Pharmaceuticals excels in Q3, poised for innovative growth

Vertex Pharmaceuticals demonstrated robust financial performance, highlighted by revenue growth and promising early launches. The company's strong R&D pipeline and strategic focus on commercialization underscore its commitment to driving innovation and growth. Addressing analyst inquiries and seizing growth opportunities will be key for Vertex's continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Vertex earnings of $1.23 per share, minus some items, beat estimates Wednesday. But $949.8 million in sales lagged narrowly.

The Top-Rated Biotech Stock Just Reported A Mixed Third Quarter

Vertex Energy (VTNR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Vertex Energy (VTNR) to Report Q3 Results: Wall Street Expects Earnings Growth

Boot Barn Hlds

Columbia Sportswear Company

Spotify

Upland Software

5 top-ranked stocks likely to beat on earnings are great investment picks for stellar gains.

Looking for an Earnings Beat? 5 Top Picks

What should investors think of this piece of news?

Vertex Pharmaceuticals Gains FDA Approval for Cystic Fibrosis Drug

Advanced Micro Devices

Alphabet

Mastercard

Google, Facebook, AMD, Mastercard and Vertex Pharmaceuticals are large caps near buy points. All five have earnings this coming week.

Google, Facebook, AMD Lead 5 Large-Cap Stocks Near Buy Points With Earnings Due

During Vertex's (VRTX) third-quarter earnings call, investor focus will be on the uptake of its newest CF drug Symdeko and the update on the recent approval of Trikafta triple combination regimen.

Can CF Drugs Drive Growth for Vertex (VRTX) in Q3 Earnings?

Costamare

DHT Holdings

First American Financial

Top Ranked Momentum Stocks to Buy for October 25th

Kansas City Southern

Lennar

PulteGroup

Skyworks Solutions

Year to date, the benchmark S&P 500 Index has rallied 20.1%, an impressive performance after a disappointing 2018, when it lost 6.6%.

5 Top Volatility-Defying S&P 500 Stocks of Past Month

It's been a big week for this fast-growing biotech.

2 Things Just Happened That Make Vertex Pharmaceuticals Stock a Screaming Buy

GlaxoSmithKline

Incyte

Jazz Pharmaceuticals

Zoetis

Let us take a look at some drug/biotech stocks that are poised to beat on earnings in the third quarter.

5 Drug/Biotech Stocks Likely to Surpass on Earnings in Q3

Biogen

Bristol-Myers

Celgene

Eli Lilly

Healthcare in particular is one such sector, with a number of large-cap biotechnology and pharmaceutical stocks enjoying fresh rallies.

5 Healthcare Stocks to Buy

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) shares were off to a flying start Tuesday, extending the late-session surge from Monday that followed a positive FDA verdict.

Vertex Shares Are Rallying: What You Need To Know

Shares of Vertex Pharmaceuticals jumped in higher-than-average volume early Tuesday after the biotech company gained FDA approval for a highly anticipated cystic fibrosis treatment.
The post Vertex Stock Jumps After Highly Anticipated CF Drug Gains Approval appeared first on Investor's Business Daily.

Vertex Stock Jumps After Highly Anticipated CF Drug Gains Approval

American Electric Power Company

Chipotle

V.F.

Verizon

Third-quarter 2019 earnings results so far are not as disappointing as expected initially. However, the forecast of overall earnings dip in the third quarter is still looming large.

5 Large-Cap Stocks Set to Beat Earnings Estimates This Month

BioMarin Pharmaceutical

BioMarin Pharmaceutical and Vertex Pharmaceuticals should prove to be outstanding growth vehicles in 2020 and beyond.

2 High-Growth Stocks to Buy Right Now

Vertex (VRTX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Can Vertex (VRTX) Keep the Earnings Surprise Streak Alive?

Amazon

Charter Communications

JD.com

Investors looking for the safety of large-cap stocks alongside impressive growth should consider these five investments.

5 Large-Cap Stocks With Growth in the Tank

The market has yet to recognize Vertex's accelerating cash flow and growing future prospects.

3 Reasons Vertex Pharmaceuticals Is Poised for a Big Year

Vertex (VRTX) inks collaboration agreement with privately-held biotech, Ribometrix, for developing up to three RNA-targeted treatments for serious diseases.

Vertex Enters Into Collaboration With Privately-Held Ribometrix

CRISPR Therapeutics

Despite working together on a major project, these two biotech stocks couldn't be more different from a growth perspective.

Forget Vertex Pharmaceuticals; CRISPR Therapeutics Is a Better Biotech Growth Stock

Amarin Corporation Plc

These biotech stocks are great picks -- but for very different reasons.

3  Top Biotech Stocks to Buy Right Now

Match Group

Revolve

More and more, the companies that we cover on Wall Street are starting to agree that while the future’s still reasonably bright for the U.S. economy, it may be one of stock market gains that are much lower than the norm has been over the past 10 years.

Jefferies Has 4 Red-Hot Growth Stocks to Buy With Huge Upside Potential

DexCom

Edwards Lifesciences

Five Below

OneSpaWorld Holdings Limited

Wall Street analysts say investors should own these stocks.

These stocks are a 'must own,' Wall Street analysts say

Conagra Brands

HollyFrontier

The stock charts of CAG, VRTX and HFC are poised to end the trading week in pivotal situations. Here's what you should know about each.

3 Big Stock Charts for Friday: Conagra Brands, HollyFrontier and Vertex Pharmaceuticals

Guardant Health Inc

Illumina

Success is in these three great healthcare stocks' DNA.

News for Vertex Pharmaceuticals Stock (VRTX)